Mehdi Poorkay, MD
Endocrinology, Diabetes & Metabolism · Louisville, KYNPI 1649265059
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,768 of the $80,924 with a category attached, or 82.5%. 29 manufacturers reported payments, led by Novo Nordisk at 33.9% of the total. Reporting peaked in 2019 at $51,463 and has fallen 99.3% since, to $355 in 2025. Among endocrinology, diabetes & metabolism clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $210.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$27K
- AstraZeneca$20K
- Boehringer Ingelheim$12K
- Johnson & Johnson$10K
- Lilly USA, LLC$6K
- Tandem Diabetes Care, Inc.$2K
- plus $3K from 23 others
What the payments were for
- Consulting fees$2,9254%
- Speaking & faculty fees$66,76883%
- Travel & lodging$4,0765%
- Food & beverage$6,9889%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 128 | $27,413 |
| AstraZeneca | 41 | $20,319 |
| Boehringer Ingelheim | 36 | $12,343 |
| Johnson & Johnson | 31 | $9,769 |
| Lilly USA, LLC | 19 | $5,931 |
| Tandem Diabetes Care, Inc. | 6 | $2,300 |
| Amgen(2 entities) | 35 | $482 |
| Sanofi-aventis U.S. LLC | 10 | $378 |
| Medtronic(2 entities) | 8 | $315 |
| Insulet Corporation | 11 | $257 |
| Shire North American Group Inc | 11 | $207 |
| Abbott | 6 | $202 |
| Amryt Pharma Holdings Ltd | 1 | $139 |
| Regeneron Healthcare Solutions, Inc. | 8 | $135 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Clarus Therapeutics Inc. | 1 | $110 |
| Antares Pharma, Inc. | 4 | $73 |
| Dexcom, Inc. | 4 | $63 |
| IBSA Pharma Inc. | 4 | $62 |
| Pfizer | 3 | $60 |
| Currax Pharmaceuticals LLC | 4 | $60 |
| AbbVie | 3 | $51 |
| Amarin Pharma, Inc. | 2 | $31 |
| Radius Health, Inc. | 2 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Senseonics, Incorporated | 1 | $17 |
| Corcept Therapeutics | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,924 in reported general payments places this provider in the 90th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,051 | $1,477,883 |
| JardianceEmpagliflozin | 377 | $453,038 |
| MounjaroTirzepatide | 273 | $320,061 |
| TrulicityDulaglutide | 184 | $310,113 |
| Tresiba Flextouch U-200Insulin Degludec | 207 | $270,709 |
| Humalog Kwikpen U-200Insulin Lispro | 52 | $233,432 |
| JanuviaSitagliptin Phosphate | 181 | $215,259 |
| FarxigaDapagliflozin Propanediol | 192 | $212,455 |
| Tresiba Flextouch U-100Insulin Degludec | 230 | $194,505 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 142 | $171,470 |
| Humalog Kwikpen U-100Insulin Lispro | 303 | $129,406 |
| Novolog FlexpenInsulin Aspart | 343 | $128,769 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $127,626 |
| Repatha SureclickEvolocumab | 94 | $115,331 |
| VascepaIcosapent Ethyl | 193 | $111,343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $27,413 | $1,563,6641,129 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $5,931 | $653,259525 claims |
| Boehringer IngelheimJardiance, Tradjenta | $12,343 | $509,934423 claims |
| AstraZenecaFarxiga | $20,319 | $212,455192 claims |
| Radius Health, Inc.Tymlos | $22 | $56,41222 claims |
| Johnson & JohnsonInvokana | $9,769 | $44,81726 claims |
| AbbVieSynthroid | $51 | $35,111378 claims |
| Esperion Therapeutics, Inc.Nexletol | $125 | $13,56023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Louisville
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
- Angelino YsonLouisville$15K
- Mary SelfLouisville$14K
- Omolara FakunleLouisville$13K
- Kaitlyn TuckerLouisville$9K
- Manikya KuritiLouisville$7K
- Carol ToumaLouisville$5K
- Swapna DeoLouisville$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.